Halozyme resumes patient enrollment and dosing in PEGPH20 clinical trial with KEYTRUDA
Halozyme announced it has resumed the enrollment and dosing of patients in its ongoing Phase 1b trial evaluating its investigational new drug, PEGPH20, in combination with KEYTRUDA (pembrolizumab) in patients with advanced non-small cell lung and gastric cancers under a revised clinical protocol. July 25, 2016